JPRN-UMIN000009485已完成未知
Safety and efficacy of allogeneic hematopoietic stem cell transplantation for refractory hematological malignancies with plerixafor-combined myeloablative conditioning - Allogeneic hematopoietic stem cell transplantation with plerixafor-combined conditioning
Division of Hematology Keio University School of Medicine0 个研究点目标入组 12 人开始时间: 2012年12月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 55years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Moderate or severe dysfunction in major organs
研究者
相似试验
尚未招募
不适用
Efficacy and safety of allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis in higher-risk myelodysplastic syndrome, chronic myelomonocytic leukemia, and secondary AML patientsKCT0004151Asan Medical Center113
已完成
1 期
Safety and efficacy of haploidentical hematopoietic stem-cell transplantation followed by post-transplant high-dose cyclophosphamidehematological malignancyJPRN-UMIN000006631niversity of Tsukuba, Department of Hematology25
已完成
1 期
Safety and efficacy of haploidentical hematopoietic stem-cell transplantation followed by post-transplant high-dose cyclophosphamide (RIC)hematological malignancyJPRN-UMIN000015694niversity of Tsukuba, Department of Hematology10
招募中
1 期
Activated NK cell therapy to negate MRD in AML patientsAcute myeloid leukemia.C92.0Acute myeloblastic leukemiaIRCT20230801058996N3Shahid Beheshti University of Medical Sciences15
已完成
不适用
Allogeneic hematopoietic stem cell transplantation for elderly patientsJPRN-UMIN000017744nivesity of Tokyo Hospital, Department of Hematology and Oncology50